
Sign up to save your podcasts
Or


In the past few months, there’s been a lot of buzz in the NET community about histotripsy. This newly-approved procedure holds a lot of promise for treating NETs, and may prove to be even more exciting in the future. In this episode of NETwise, we’re going to tell you everything we know about this new treatment: how it works, how it came to be, and what it means for NET patients.
Thank you to Mary Seibert for sharing her NET story.
Osman Ahmed, MD is an interventional radiologist at the University of Chicago.
Zhen Xu, Phd, is one of the inventors of histotripsy, and one of the founders of HistoSonics, the company that makes histotripsy devices. She’s a professor of biomedical engineering, radiology, and neurosurgery at the University of Michigan.
The post NETWise Episode 35: Histotripsy appeared first on NETRF.
By Neuroendocrine Tumor Research Foundation (NETRF)4.8
4545 ratings
In the past few months, there’s been a lot of buzz in the NET community about histotripsy. This newly-approved procedure holds a lot of promise for treating NETs, and may prove to be even more exciting in the future. In this episode of NETwise, we’re going to tell you everything we know about this new treatment: how it works, how it came to be, and what it means for NET patients.
Thank you to Mary Seibert for sharing her NET story.
Osman Ahmed, MD is an interventional radiologist at the University of Chicago.
Zhen Xu, Phd, is one of the inventors of histotripsy, and one of the founders of HistoSonics, the company that makes histotripsy devices. She’s a professor of biomedical engineering, radiology, and neurosurgery at the University of Michigan.
The post NETWise Episode 35: Histotripsy appeared first on NETRF.

43,566 Listeners

56,477 Listeners

59 Listeners

15,423 Listeners

2 Listeners

621 Listeners

2 Listeners